MEPSEVII™ (vestronidase alfa-vjbk)

LENGTH OF AUTHORIZATION: UP TO ONE YEAR

REVIEW CRITERIA:
- Patient must have a diagnosis of Mucopolysaccharidosis type VII (Sly syndrome) confirmed in medical records or patient health conditions.

DOsing:
- Recommended dosing is 4mg/kg body weight administered intravenously over 4 hours every 2 weeks.